100 episodes

Our podcast is here to help humanize Alzheimer’s disease, by speaking with the experts in our community to keep you informed on the latest headlines, research studies, and caregiver resources.

Dementia Matters Wisconsin Alzheimer‘s Disease Research Center

    • Health & Fitness
    • 4.5 • 85 Ratings

Our podcast is here to help humanize Alzheimer’s disease, by speaking with the experts in our community to keep you informed on the latest headlines, research studies, and caregiver resources.

    The Future of the Alzheimer’s Association: Interview with Dr. Joanne Pike and Harry Johns

    The Future of the Alzheimer’s Association: Interview with Dr. Joanne Pike and Harry Johns

    In October 2022, the Alzheimer's Association named Dr. Joanne Pike, the current president of the Association, as the next CEO, succeeding Harry Johns who has served as CEO since 2005. In this episode, Pike and Johns join the podcast to share their insights on how the Alzheimer's Association has grown over the past few decades and the future plans of the association, as well as the next steps in Alzheimer's treatment from both community and medication perspectives.
    Guests: Joanne Pike, DrPH, president and CEO, Alzheimer’s Association, Alzheimer’s Impact Movement, and Harry Johns, former CEO, Alzheimer's Association, former CEO and president, Alzheimer's Impact Movement (AIM), trustee and former chair, World Dementia Council
    Show Notes
    Learn more about CMS's updated coverage on monoclonal antibody treatment and the Alzheimer's Association’s response at their website.
    Learn more about Part the Cloud at their website.
    Learn more about the Alzheimer's Association at their website.
    Learn more about Dr. Pike in her bio on her website.
    Learn more about Mr. Johns in his bio on his website.
    Connect with us
    Find transcripts and more at our website.
    Email Dementia Matters: dementiamatters@medicine.wisc.edu
    Follow us on Facebook and Twitter.
    Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

    • 32 min
    Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval

    Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval

    Host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.
    Show Notes
    In the coming weeks, host Nathaniel Chin will be joined by Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to further discuss lecanemab and the clinical trials’ results. A link to that episode will be added here following its release.
    Read the FDA’s news release regarding lecanemab’s accelerated approval on their website.
    Connect with us
    Find transcripts and more at our website.
    Email Dementia Matters: dementiamatters@medicine.wisc.edu
    Follow us on Facebook and Twitter.
    Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

    • 20 min
    Healthy Habits for the New Year and Modifiable Risk Factors for Alzheimer’s Disease

    Healthy Habits for the New Year and Modifiable Risk Factors for Alzheimer’s Disease

    Host Nathaniel Chin, MD, starts the new year by discussing modifiable risk factors for Alzheimer’s disease, commenting on building healthy lifestyle habits for the new year, and reflecting as Dementia Matters celebrates five years of production.
    Show Notes
    “Dementia prevention, intervention, and care: 2020 report of the Lancet Commission” is mentioned at the 4:16 mark. Read the full report on The Lancet’s website.
    Our past episode, “Alcohol and the Brain: One Drink a Day Associated with Brain Shrinkage,” is mentioned at the 5:05 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen. 
    Our past episode, “Study Finds Air Pollution a Risk Factor For Alzheimer’s Disease,” is mentioned at the 5:07 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen.
    Our past episode, “AARP Study Show Stigma Surrounding Dementia Among Healthcare Professionals And General Public,” is mentioned at the 5:28 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen.
    As mentioned at the 7:40 mark, learn more about the books The Power of Habit by Charles Duhigg and Atomic Habits by James Clear, on the authors’ respective websites.
    Listen to our past episode, “Impacts of Exercise on Brain Health,” mentioned at the 9:37 mark.
    Learn about the book, Why Sleep Matters by Matthew Walker, mentioned at the 11:14 mark.
    Connect with us
    Find transcripts and more at our website.
    Email Dementia Matters: dementiamatters@medicine.wisc.edu
    Follow us on Facebook and Twitter.
    Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

    • 14 min
    Bioenergetics: How Mitochondria Affects Alzheimer’s Disease and Aging

    Bioenergetics: How Mitochondria Affects Alzheimer’s Disease and Aging

    It’s generally known that mitochondria are the powerhouse of cells, but did you know they can play a significant role in aging processes? Through the field of bioenergetics, scientists are looking to study how changes in mitochondria affect us as we age and their connection to Alzheimer’s disease. Dr. Russell Swerdlow joins the podcast to discuss the field of bioenergetics and how mitochondria can impact Alzheimer’s disease and other aspects of aging.
    Guest: Russell Swerdlow, MD, director, Kansas Alzheimer’s Disease Research Center, director, Heartland Center for Mitochondrial Medicine, professor of neurology, University of Kansas
    Show Notes
    Learn more about Dr. Russell Swerdlow at his bio on the University of Kansas Medical Center’s website.
    Connect with us
    Find transcripts and more at our website.
    Email Dementia Matters: dementiamatters@medicine.wisc.edu
    Follow us on Facebook and Twitter.
    Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

    • 25 min
    Looking Toward the Future: How Preclinical Alzheimer’s Disease Biomarker Disclosures Impact Society

    Looking Toward the Future: How Preclinical Alzheimer’s Disease Biomarker Disclosures Impact Society

    The field of biomarkers is advancing quickly, allowing preclinical Alzheimer’s disease to be identified earlier and earlier in a person’s life. As individuals learn they are at risk for Alzheimer’s years or even decades before experiencing cognitive decline, what does this mean for them and for society as a whole? Drs. Emily Largent and Claire Erickson join the podcast to discuss ten key areas, such as healthcare, insurance, and direct-to-consumer testing, that should be addressed to support those at risk for cognitive decline and broader U.S. society as biomarker testing and disclosures become more prominent.
    Guests: Emily Largent, PhD, RN, Emanuel and Robert Hart Assistant Professor, University of Pennsylvania Perelman School of Medicine, and Claire Erickson, PhD, MPA, postdoctoral fellow, University of Pennsylvania Perelman School of Medicine
    Show Notes
    Read Drs. Emily Largent and Claire Erickson’s paper, “Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society,” on PubMed Central. 
    Learn more about Dr. Largent at her bio on the Penn Leonard Davis Institute of Health Economics website.
    Learn more about Dr. Erickson at her bio on the Penn Leonard Davis Institute of Health Economics website.
    Connect with us
    Find transcripts and more at our website.
    Email Dementia Matters: dementiamatters@medicine.wisc.edu
    Follow us on Facebook and Twitter.
    Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

    • 37 min
    Mixed Dementia, Explained

    Mixed Dementia, Explained

    Though brain and cognitive changes are typically diagnosed as one form of dementia, recent studies have shown that mixed dementia is more common than previously thought. Mixed dementia, also known as Multiple-etiology dementia, is a condition where brain changes are caused by more than one neurological disease, such as Alzheimer’s disease, Lewy body dementia (LBD), or frontotemporal dementia. Dr. Roderick Corriveau joins the podcast to discuss what is known about mixed dementia and how the field of studying neurological diseases is advancing to diagnose and treat this condition.
    Guest: Roderick Corriveau, PhD, program director, National Institute of Neurological Disorders and Stroke (NINDS), NIH Lead, Alzheimer’s Disease-Related Dementias (ADRD) Summits
    Show Notes
    Read more about the National Institutes of Neurological Disorders and Stroke (NINDS) campaign, “Mind Your Risks,” at the Mind Your Risks website.
    Learn more about mixed dementia on the Alzheimer’s Association website.
    Learn more about Dr. Corriveau at his bio on the National Institutes of Neurological Disorders and Stroke website.
    Learn more about NINDS on their website.
    Connect with us
    Find transcripts and more at our website.
    Email Dementia Matters: dementiamatters@medicine.wisc.edu
    Follow us on Facebook and Twitter.
    Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

    • 28 min

Customer Reviews

4.5 out of 5
85 Ratings

85 Ratings

Mikep 2 ,

Dementia Matters

This podcast is very helpful to me as a caregiver to my wife as she goes through MCI to now more advanced issues. This podcast helps me to learn and understand cognitive impairment and what I might possibly do to provide better care. We are blessed with quality Family and Memory Doctors. This podcast gives me more understanding and how I might possibly better relate to our Doctors.

Zombie Ho ,

Thanks so much.

Thank you for this. I’m only 23 and helping my grandmother caring for my grandfather through this journey and you’re right, there’s so little on it. I’m a part of the google generation. I’m used to looking something up and finding hundreds of articles, forums, podcasts, YouTube videos, and support communities and there’s surprisingly little on this. Maybe because the google gen isn’t quite dealing with this yet, all the support groups I find are just a few middle age people talking and giving each other tips and support. And also the research itself is really just now taking off and being understood. Either way. I’m very happy for this resource.

Hatchet Right ,

Mindfulness

The least likely of all your podcasts that I think is relevant

Top Podcasts In Health & Fitness

Scicomm Media
Jay Shetty
Kathryn Nicolai
Ten Percent Happier
Aubrey Gordon & Michael Hobbes
Cameron Hanes

You Might Also Like

Hidden Brain, Shankar Vedantam
NPR
Pushkin Industries
Johns Hopkins Bloomberg School of Public Health
On Being Studios
TED